Abstract
Background & Aims: The intestinal barrier protects intestinal cells from microbes and antigens in the lumen—breaches can alter the composition of the intestinal microbiota, the enteric immune system, and metabolism. We performed a screen to identify molecules that disrupt and support the intestinal epithelial barrier and tested their effects in mice. Methods: We performed an imaging-based, quantitative, high-throughput screen (using CaCo-2 and T84 cells incubated with lipopolysaccharide; tumor necrosis factor; histamine; receptor antagonists; and libraries of secreted proteins, microbial metabolites, and drugs) to identify molecules that altered epithelial tight junction (TJ) and focal adhesion morphology. We then tested the effects of TJ stabilizers on these changes. Molecules we found to disrupt or stabilize TJs were administered mice with dextran sodium sulfate-induced colitis or Citrobacter rodentium-induced intestinal inflammation. Colon tissues were collected and analyzed by histology, fluorescence microscopy, and RNA sequencing. Results: The screen identified numerous compounds that disrupted or stabilized (after disruption) TJs and monolayers of epithelial cells. We associated distinct morphologic alterations with changes in barrier function, and identified a variety of cytokines, metabolites, and drugs (including inhibitors of actomyosin contractility) that prevent disruption of TJs and restore TJ integrity. One of these disruptors (putrescine) disrupted TJ integrity in ex vivo mouse colon tissues; administration to mice exacerbated colon inflammation, increased gut permeability, reduced colon transepithelial electrical resistance, increased pattern recognition receptor ligands in mesenteric lymph nodes, and decreased colon length and survival times. Putrescine also increased intestine levels and fecal shedding of viable C rodentium, increased bacterial attachment to the colonic epithelium, and increased levels of inflammatory cytokines in colon tissues. Colonic epithelial cells from mice given putrescine increased expression of genes that regulate metal binding, oxidative stress, and cytoskeletal organization and contractility. Co-administration of taurine with putrescine blocked disruption of TJs and the exacerbated inflammation. Conclusions: We identified molecules that disrupt and stabilize intestinal epithelial TJs and barrier function and affect development of colon inflammation in mice. These agents might be developed for treatment of barrier intestinal impairment-associated and inflammatory disorders in patients, or avoided to prevent inflammation.
| Original language | English |
|---|---|
| Pages (from-to) | 1807-1823 |
| Number of pages | 17 |
| Journal | Gastroenterology |
| Volume | 159 |
| Issue number | 5 |
| DOIs | |
| State | Published - Nov 2020 |
Bibliographical note
Publisher Copyright:© 2020 AGA Institute
Funding
Funding D.Z. is the recipient of the European Crohn’s and Colitis Organization Fellowship and is supported by the Ke Lin Program of the First Affiliated Hospital, Sun Yat-sen University. H.S. is supported by The V.R. Schwartz Research Fellow Chair. E. Elinav is supported by Yael and Rami Ungar, the Leona M. and Harry B. Helmsley Charitable Trust , Adelis Foundation, Pearl Welinsky Merlo Scientific Progress Research Fund, Lawrence and Sandra Post Family Foundation, Daniel Morris Trust, Park Avenue Charitable Fund, The Hanna and Dr. Ludwik Wallach Cancer Research Fund, Howard and Nancy Marks Charitable Fund, Aliza Moussaieff, Estate of Malka Moskowitz, Estate of Myron H. Ackerman, Estate of Bernard Bishin for the WIS-Clalit Program, Donald and Susan Schwarz, and by grants funded by the European Research Council , Israel Science Foundation , Israel Ministry of Science and Technology, Israel Ministry of Health, the Helmholtz Foundation, Else Kroener Fresenius Foundation, Garvan Institute , European Crohn’s and Colitis Organization, Deutsch-Israelische Projektkooperation, and Wellcome Trust . E.E. is the incumbent of the Sir Marc and Lady Tania Feldmann Professorial Chair; a senior fellow, Canadian Institute of Advanced Research; and an international scholar, The Bill & Melinda Gates Foundation and Howard Hughes Medical Institute . B.G. is the incumbent of the Erwin Neter Chair in Cell and Tumor Biology. Funding D.Z. is the recipient of the European Crohn's and Colitis Organization Fellowship and is supported by the Ke Lin Program of the First Affiliated Hospital, Sun Yat-sen University. H.S. is supported by The V.R. Schwartz Research Fellow Chair. E. Elinav is supported by Yael and Rami Ungar, the Leona M. and Harry B. Helmsley Charitable Trust, Adelis Foundation, Pearl Welinsky Merlo Scientific Progress Research Fund, Lawrence and Sandra Post Family Foundation, Daniel Morris Trust, Park Avenue Charitable Fund, The Hanna and Dr. Ludwik Wallach Cancer Research Fund, Howard and Nancy Marks Charitable Fund, Aliza Moussaieff, Estate of Malka Moskowitz, Estate of Myron H. Ackerman, Estate of Bernard Bishin for the WIS-Clalit Program, Donald and Susan Schwarz, and by grants funded by the European Research Council, Israel Science Foundation, Israel Ministry of Science and Technology, Israel Ministry of Health, the Helmholtz Foundation, Else Kroener Fresenius Foundation, Garvan Institute, European Crohn's and Colitis Organization, Deutsch-Israelische Projektkooperation, and Wellcome Trust. E.E. is the incumbent of the Sir Marc and Lady Tania Feldmann Professorial Chair; a senior fellow, Canadian Institute of Advanced Research; and an international scholar, The Bill & Melinda Gates Foundation and Howard Hughes Medical Institute. B.G. is the incumbent of the Erwin Neter Chair in Cell and Tumor Biology.We thank the members of the Elinav and Geiger Laboratories and members of the Deutsches Krebsforschungszentrum Cancer-Microbiome Division for excellent discussions and advice. We thank Dr Noga Kozer and Dr Haim Barr, from the Wohl Drug Discovery team of the Nancy and Stephen Grand, Israel National Center for Personalized Medicine of the Weizmann Institute of Science, for their expert help with the design and execution of the high-throughput screening described herein. We thank Dr Richard Elliot and Dr Chris Damen, Bill & Melinda Gates Foundation, for fruitful discussions. Inna Grosheva, PhD (Data curation: Lead; Formal analysis: Lead; Investigation: Lead; Methodology: Lead; Validation: Lead; Visualization: Lead; Writing ? original draft: Equal; Writing ? review & editing: Equal). Danping Zheng, MD (Data curation: Lead; Formal analysis: Lead; Investigation: Lead; Methodology: Lead; Visualization: Equal; Writing ? original draft: Equal; Writing ? review & editing: Equal). Maayan Levy, PhD (Data curation: Supporting; Investigation: Supporting). Omer Polansky, MSc (Data curation: Supporting; Formal analysis: Supporting; Visualization: Supporting). Alexandra Lichtenstein, PhD (Data curation: Supporting; Formal analysis: Supporting; Investigation: Supporting). Ofra Golani, MSc (Formal analysis: Supporting; Software: Lead). Mally Bachas-Dori, PhD (Investigation: Supporting; Methodology: Supporting; Resources: Supporting). Claudia Moresi, MSc (Investigation: Supporting; Methodology: Supporting). Hagit Shapiro, PhD (Investigation: Supporting; Methodology: Supporting; Resources: Supporting). Sara Del Mare-Roumani, PhD (Investigation: Supporting; Methodology: Supporting; Resources: Supporting). Rafael Valdes-Mas, PhD (Data curation: Supporting; Formal analysis: Supporting; Validation: Supporting). Yiming He, MD (Methodology: Supporting; Validation: Supporting). Hodaya Karbi, BSc (Data curation: Supporting; Formal analysis: Supporting; Investigation: Supporting). Minhu Chen, MD, PhD (Investigation: Supporting; Resources: Supporting; Visualization: Supporting). Alon Harmelin, PhD (Investigation: Supporting; Methodology: Supporting; Resources: Supporting). Conflicts of interest The authors disclose the following: E.E. is a consultant to DayTwo and BiomX. None of the topics related to this work involve these or other commercial entities. None of the other authors have any financial or nonfinancial competing interest.
| Funders |
|---|
| Daniel Morris Trust |
| Deutsch-Israelische Projektkooperation |
| Elinav and Geiger Laboratories |
| Else Kroener Fresenius Foundation |
| European Crohn's and Colitis Organization |
| European Crohn’s and Colitis Organization |
| European Research Council , Israel Science Foundation |
| European Research Council, Israel Science Foundation |
| Helmholtz Foundation |
| Howard and Nancy Marks Charitable Fund |
| Israel Ministry of Science and Technology, Israel Ministry of Health |
| Ke Lin Program of the First Affiliated Hospital |
| Lawrence and Sandra Post Family Foundation |
| Park Avenue Charitable Fund |
| Pearl Welinsky Merlo Scientific Progress Research Fund |
| Wohl Drug Discovery team of the Nancy and Stephen Grand, Israel National Center for Personalized Medicine of the Weizmann Institute of Science |
| Yael and Rami Ungar |
| Howard Hughes Medical Institute |
| Bill and Melinda Gates Foundation |
| Leona M. and Harry B. Helmsley Charitable Trust |
| Canadian Institute for Advanced Research |
| Wellcome Trust |
| Sun Yat-Sen University |
| Else Kröner-Fresenius-Stiftung |
| Garvan Institute of Medical Research |
| Ministry of science and technology, Israel |
| Helmholtz Association |
Keywords
- Cytokine
- IBD
- Microbiota
- Model